Preliminary anti-Coxsackie activity of novel 1-[4-(5,6-dimethyl(H)-1H(2H)-benzotriazol-1(2)-yl)phenyl]-3-alkyl(aryl)ureas.

BACKGROUND Coxsackievirus infections are associated with cases of aseptic meningitis, encephalitis, myocarditis, and some chronic disease. METHOD A series of benzo[d][1,2,3]triazol-1(2)-yl derivatives (here named benzotriazol-1(2)-yl) (4a-i, 5a-h, 6a-e, g, i, j and 7a-f, h-j) were designed, synthesized and in vitro evaluated for cytotoxicity and antiviral activity against two important human enteroviruses (HEVs) members of the Picornaviridae family [Coxsackievirus B 5 (CVB-5) and Poliovirus 1 (Sb-1)]. RESULT Compounds 4c (CC50 >100 μM; EC50 = 9 μM), 5g (CC50 >100 μM; EC50 = 8 μM), and 6a (CC50 >100 μM; EC50 = 10 μM) resulted interestingly active against CVB-5. With the aim of evaluating the selectivity of action of this class of compounds, a wide spectrum of RNA (positive- and negative-sense), double-stranded (dsRNA) or DNA viruses were also assayed. For none of them, significant antiviral activity was determined. CONCLUSION Taken together these results point towards a selective activity against CVB-5, an important human pathogen that causes both acute and chronic diseases in infants, young children, and immunocompromised patients.

[1]  E. Laurini,et al.  Dichloro-Phenyl-Benzotriazoles: A New Selective Class of Human Respiratory Syncytial Virus Entry Inhibitors , 2019, Front. Chem..

[2]  R. Loddo,et al.  Antiviral activities of 5-chlorobenzotriazole derivatives , 2018, Monatshefte für Chemie - Chemical Monthly.

[3]  E. Laurini,et al.  Quinoxaline derivatives as new inhibitors of coxsackievirus B5. , 2017, European journal of medicinal chemistry.

[4]  P. Simmonds,et al.  ICTV Virus Taxonomy Profile: Picornaviridae , 2017, The Journal of general virology.

[5]  M. Kalenga,et al.  [EARLY ENTEROVIRUS NEONATAL INFECTION: WHEN SHOULD WE THINK ABOUT IT?]. , 2016, Revue medicale de Liege.

[6]  P. Krogstad,et al.  Enteroviruses in the early 21st century: new manifestations and challenges , 2016, Current opinion in pediatrics.

[7]  E. Laurini,et al.  Synthesis, cytotoxicity and antiviral evaluation of new series of imidazo[4,5-g]quinoline and pyrido[2,3-g]quinoxalinone derivatives. , 2015, European journal of medicinal chemistry.

[8]  A. Sparatore,et al.  Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5. , 2015, Bioorganic & medicinal chemistry.

[9]  R. Tellier,et al.  Coxsackie Virus A16 Infection of Placenta with Massive Perivillous Fibrin Deposition Leading to Intrauterine Fetal Demise at 36 Weeks Gestation , 2015, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[10]  G. Sanna,et al.  Antiviral properties from plants of the Mediterranean flora , 2015, Natural product research.

[11]  I. Briguglio,et al.  Benzotriazole: An overview on its versatile biological behavior , 2014, European Journal of Medicinal Chemistry.

[12]  I. Briguglio,et al.  Synthesis and antiviral activity of new phenylimidazopyridines and N-benzylidenequinolinamines derived by molecular simplification of phenylimidazo[4,5-g]quinolines. , 2014, European journal of medicinal chemistry.

[13]  S. Dowell,et al.  What we are watching—five top global infectious disease threats, 2012: a perspective from CDC’s Global Disease Detection Operations Center , 2013, Emerging health threats journal.

[14]  Tom J. Petty,et al.  Picornavirus and enterovirus diversity with associated human diseases. , 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[15]  I. Briguglio,et al.  Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors. , 2011, Bioorganic & medicinal chemistry.

[16]  Jian-Dong Jiang,et al.  Synthesis, structure-activity relationship and in vitro biological evaluation of N-arylethyl isoquinoline derivatives as Coxsackievirus B3 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[17]  E. Laurini,et al.  3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors. , 2011, European journal of medicinal chemistry.

[18]  José L. Medina-Franco,et al.  Benzotriazoles and Indazoles Are Scaffolds with Biological Activity against Entamoeba histolytica , 2011, Journal of biomolecular screening.

[19]  Rongmei Gao,et al.  Synthesis and antiviral activities of synthetic glutarimide derivatives. , 2010, Chemical & pharmaceutical bulletin.

[20]  J. Neyts,et al.  9-Arylpurines as a novel class of enterovirus inhibitors. , 2010, Journal of medicinal chemistry.

[21]  Zhan-Qiu Yang,et al.  Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo , 2009, Archives of Virology.

[22]  M. Marchetti,et al.  LC-MS analysis of trimethoxyamphetamine designer drugs (TMA series) from urine samples. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[23]  M. Ferrone,et al.  Synthesis and anti-picornaviridae in vitro activity of a new class of helicase inhibitors the N,N'-bis[4-(1H(2H)-benzotriazol-1(2)-yl)phenyl] alkyldicarboxamides. , 2007, Medicinal chemistry (Shariqah (United Arab Emirates)).

[24]  M. Ferrone,et al.  Synthesis and in vitro evaluation of the anti-viral activity of N-[4-(1H(2H)-benzotriazol-1(2)-yl)phenyl]alkylcarboxamides. , 2006, Medicinal chemistry (Shariqah (United Arab Emirates)).

[25]  S. Cannas,et al.  In vitro activity of new quinoxalin 1,4-dioxide derivatives against strains of Mycobacterium tuberculosis and other mycobacteria. , 2005, International journal of antimicrobial agents.

[26]  Sarah Schalinski,et al.  Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. , 2003, European journal of biochemistry.

[27]  A. Carta,et al.  Choleretic activity of 3-[ring substituted benzotriazol-1(2)-yl]alkanoic and alkenoic acids. , 1994, Farmaco.

[28]  R. Fromtling.  Overview of medically important antifungal azole derivatives , 1988, Clinical Microbiology Reviews.